Altimmune, Inc. (ALT) — Inside-Filings

Sentiment-Signal

9,5

Stark Bearisch

Composite Score (0–100)

Insider (25%)

Keine Insider-Käufe

Institutionell (22,5%)

Keine neuen Positionen

Aktivist (12,5%)

Kein 13D/13G

Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)

Score-Verlauf (90 Tage)

Stammdaten

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Unternehmen & Branche

Name	Altimmune, Inc.
Ticker	ALT
CIK	0001326190
Boerse	US
Sektor	Healthcare
Industrie	Biotechnology
SIC	2834 · Pharmaceutical Preparations

Wertpapier & Kennzahlen

CUSIP	–
ISIN	–
Typ	Common Stock
Marktkapitalisierung	233,1 Mio. USD
Beta	0,34
Dividendenrendite	0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

Periode	Filing	Umsatz	Nettoergebnis	EPS	Aktiva	Eigenkapital
2025-12-31	10-K	41,000	-88,093,000	-1.00	279,929,000	224,892,000
2025-09-30	10-Q	5,000	-19,014,000	-0.21	218,447,000	185,601,000
2025-06-30	10-Q	5,000	-22,146,000	-0.27	190,350,000	161,367,000
2025-03-31	10-Q	5,000	-19,575,000	-0.26	157,263,000	142,162,000
2024-12-31	10-K	20,000	-95,059,000	-1.34	139,306,000	123,508,000
2024-09-30	10-Q	5,000	-22,845,000	-0.32	147,864,000	133,377,000
2024-06-30	10-Q	5,000	-24,640,000	-0.35	173,346,000	152,531,000
2024-03-31	10-Q	5,000	-24,394,000	-0.34	188,358,000	172,937,000
2023-12-31	10-K	426,000	-88,447,000	-1.66	210,640,000	194,099,000
2023-09-30	10-Q	362,000	-20,671,000	-0.39	166,573,000	150,397,000
2023-06-30	10-Q	6,000	-16,061,000	-0.32	183,316,000	167,714,000
2023-03-31	10-Q	21,000	-20,074,000	-0.40	187,083,000	167,732,000
2022-12-31	10-K	-68,000	-84,713,000	-1.81	206,928,000	185,293,000
2022-09-30	10-Q	2,000	-23,516,000	-0.48	225,277,000	205,029,000
2022-06-30	10-Q	8,000	-20,107,000	-0.42	209,906,000	194,535,000
2022-03-31	10-Q	32,000	-19,430,000	-0.44	205,660,000	184,868,000
2021-12-31	10-K	4,410,000	-97,090,000	-2.35	218,865,000	199,135,000
2021-09-30	10-Q	158,000	-33,510,000	-0.81	236,906,657	209,264,000
2021-06-30	10-Q	137,000	-24,827,000	-0.60	257,260,850	241,278,000
2021-03-31	10-Q	838,000	-14,864,000	-0.38	264,250,758	246,437,000

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

Datum	Insider	Rolle	Typ	Stückzahl	Kurs	Wert (USD)	Δ
2026-04-01	WEAVER GREGORY L	Officer, Chief Financial Officer	Open Market Purchase	10,000	3.15	31,499.00	+101,9%
2026-03-06	WEAVER GREGORY L	Officer, Chief Financial Officer	Open Market Purchase	5,000	3.54	17,700.00	+57,2%
2026-03-06	Durso Jerome Benedict	Director, Officer, President and CEO	Open Market Purchase	20,000	3.54	70,790.00	+229,0%
2026-01-08	Pisano Wayne	Director	Open Market Purchase	5,000	4.08	20,410.00	+66,0%
2026-01-05	Sohn Catherine A.	Director	Open Market Purchase	500	4.24	2,117.55	+6,8%
2025-12-29	Jorkasky Diane	Director	Open Market Purchase	527	3.80	2,002.60	+6,5%
2025-12-23	GILL JOHN	Director	Open Market Purchase	12,500	4.10	51,250.00	+165,8%
2025-12-22	Durso Jerome Benedict	Director	Open Market Purchase	12,500	4.13	51,568.75	+166,8%

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.